BRCA1 and neoplasm: Poly(ADP-ribose) polymerase inhibitors (PARPi) are a drug class that targets PARP 1, effectively disrupting the tumor's self-repair mechanism and leading to apoptosis.5 This drug class has shown synthetic lethality in tumor cells that lack BRCA1/2 activity.